India, Nov. 9 -- Hemab Therapeutics, Inc. (COAG), a clinical-stage biotechnology company developing treatments for blood coagulation disorders, announced the initiation of SOLARA, a pivotal Phase 3 trial evaluating investigational sutacimig (HMB-001) as a preventive treatment for Glanzmann thrombasthenia (GT).
Glanzmann thrombasthenia is a rare, inherited bleeding disorder caused by defective platelet function, which prevents blood from clotting properly.
Patients can experience frequent and sometimes severe bleeding episodes. Currently, no prophylactic treatment is approved to prevent bleeding in people with GT.
Sutacimig is an investigational, once-weekly subcutaneous bispecific antibody designed to compensate for platelet dysfunction ...